Shuyan Wu
Ziqi Sui
Jie Pan
Xiao Men4
Yimin Shen- 1The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
- 2Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
- 3Department of Endocrinology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang Province, China
- 4Qingdao Mingyue Seaweed Group Co.Ltd. National Key Laboratory of Marine Food Processing and Safety Control, Qingdao, Shandong Province, China
- 5Jinhua Institute of Zhejiang University, Zhejiang University, Jinhua, China
- 6School of Pharmacy, Zhejiang University, Hangzhou, Zhejiang Province, China
Metabolic disorders are precursors to numerous chronic diseases. Phlorotannins is a kind of natural bioactive agents found in brown algae composed with polyphenolic. Due to its role in regulating blood glucose and lipid levels, it is expected to manage chronic metabolic disease. However, previous study has mainly focused phlorotannins on their metabolic effects in the native state. Due to their high molecular weight, these compounds are poorly absorbed in the intestine, which limits their oral bioavailability. This review examines the interactions between phlorotannins and gut microbiota, as well as the role of small-molecule metabolites produced by microbial degradation on host metabolism. Phlorotannins can modulate the composition of the gut microbiota, promote the production of short-chain fatty acids, and increase bile acid metabolism. Therefore, understanding the bioavailability of gut microbiota-derived phlorotannin metabolites is crucial for developing strategies to prevent obesity and manage diabetes.
1 Introduction
Obesity, which is defined as a body mass index (BMI) > 30 kg/m2, is among the primary risk factors for metabolic disorders. The global obesity rate is projected to surpass 6% in men and 9% in women by 2025 (1). Obesity contributes to increased risks of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), hypertension, nonalcoholic fatty liver disease (NAFLD), neurodegenerative diseases (2), and certain cancers. Among these, T2DM is the most common type of diabetes, accounting for approximately 90% of all cases (3). By 2035, population with type 2 diabetes is expected to reach 592 million (4), which puts a growing health burden on the world. The maintenance of stable postprandial blood glucose is vital for health. Chronic postprandial hyperglycemia drives increased glycated hemoglobin levels, contributing to the development of diabetes, lipid metabolism disorders, and CVD (5). Current pharmacological treatments for these conditions can control disease progression but are often associated with adverse effects. The management of metabolic diseases typically involves dietary interventions, physical exercise, and the hypoglycemic and lipid-lowering drugs. However, these medications frequently cause gastrointestinal side effects. Consequently, exploring natural alternatives to improve the quality of life for affected individuals has attracted growing interest.
Over the past few decades, marine algae resources have attracted attention for their bioavailable value because of their potential in the food, cosmetics, and pharmaceutical industries. Various secondary metabolites of algae have been investigated for their diverse functional properties, such as antioxidant (6), anti-inflammatory (7, 8), anticancer (9), antidiabetic (10), antibacterial (11), immunomodulatory, and antihypertensive effects (12). These metabolites include polyphenols, polysaccharides, terpenoids, alkaloids, polyunsaturated fatty acids, proteins, peptides, amino acids, and halogenated derivatives of polyphenols. Tannins are a unique class of phenolic metabolites with molecular weights ranging from 500 to 30,000 Da and are widely distributed in almost all plant-based foods and beverages (13).
Recent studies have shown that polyphenols from marine organisms have remarkable pharmacological potential in metabolic disorders (14). Algal polyphenols include phenolic acids, phlorotannins, flavonoids, and halogenated derivatives (15). Phlorotannins, a class of polyphenols derived from brown algae, have gained significant interest due to their strong antibacterial and cytotoxic activities. In addition, their wide distribution in temperate and polar marine environments make them a promising source of marine biomass. However, the high molecular weight of these compounds limits their direct absorption and oral bioavailability. Nevertheless, recent studies show that the gut microbiota can degrade phlorotannins, which increases their pharmacological activity and helps improve metabolic health in the host (16). The gut microbiota, a complex community of microorganisms residing in the colon, plays a fundamental role in human physiology (17). For example, the gut microbiota regulates host energy homeostasis, including energy production, storage, and expenditure (18). Since intestinal glucose absorption is influenced by the gut environment and glucose transport rates, it is critical to understand how phlorotannins affect the processes, including digestive enzyme activity and glucose transport, to better elucidate their mechanism in regulating postprandial blood glucose. Studies have shown that extra seaweed into the diet can change the diversity of the gut microbiota in the host, which suggest bioactive phenolic compounds may be related to the microbial changes.
This review aims to: (i) summarize the species and distribution of brown algae while comparing the properties of marine-derived phlorotannins with terrestrial polyphenols; (ii) analyze the role of the gut microbiota in enhancing the bioavailability of phlorotannins; (iii) systematically elucidate the small-molecule metabolites derived from microbial degradation of phlorotannins and their functions in metabolic regulation; and (iv) summarize the current evidence from preclinical and clinical studies on the metabolic effects of phlorotannins.
2 Sources, structural diversity and unique traits of phlorotannins
2.1 Species and distribution of brown algae (Phaeophyceae)
Marine ecosystems are rich sources of bioactive compounds. Seaweeds are major producers in marine environments and are sources of various bioactive compounds, accounting for 40% of global photosynthesis (19). There are approximately 10,000 species of seaweed worldwide, classified as brown, red or green algae on the basis of their pigmentation. Brown seaweeds contain higher concentrations of bioactive components than red and green seaweeds do (20). Among brown seaweed species, Ascophyllum nodosum and Fucus vesiculosus exhibit the highest antioxidant values and total phenolic content (21).
The Phaeophyceae family (Fucaceae) is a dominant algal group in the intertidal zones of cold to warm-temperate Northern Hemisphere regions, encompassing genera such as Ascophyllum, Fucus, Pelvetia, Pelvetiopsis, and Silvetia. Among these, Fucus is the most prominent and widely distributed genus, comprising 66 recognized species. The dominant phlorotannins in Fucus spp. are fucophlorethols, characterized by molecular weights of 370–746 Da and a relatively low degree of polymerization (3–6 phloroglucinol units, PGU) (22). Studies have reported that the ethyl acetate extract of Ecklonia cava (EC-ETAC) exerts anti-obesity effects on 3 T3-L1 preadipocytes via the HO-1/Nrf2 pathway (23). Specifically, EC-ETAC significantly suppressed the expression of key adipogenic transcription factors (PPARγ, C/EBPα, and SREBP-1) and related proteins (FAS and LPL), indicating its role in promoting lipolysis and brown adipose tissue formation. Furthermore, within the Phaeophyceae family, Ascophyllum and Pelvetia are monotypic genera endemic to the North Atlantic, represented by A. nodosum (knotted wrack) and P. canaliculata (channeled wrack), respectively. In contrast, Pelvetiopsis and Silvetia are endemic to the North Pacific (24–26).
Algae produce a wide spectrum of secondary metabolites, including polyphenols, polysaccharides, terpenoids, alkaloids, and halogenated derivatives (26). Commonly identified polyphenols encompass phlorotannins, catechins, bromophenols, and fucoxanthin, among others (27). In particular, brown algae are distinguished by their high phlorotannin content, which can reach 25% of dry weight, whereas red and green algae predominantly contain phenolic acids and flavonoids (28, 29). Remarkably, although most brown algae synthesize phlorotannins with up to 39 phloroglucinol units, P. canaliculata produces polymers of up to 49 units—possibly related to its adaptation to extreme habitats (30). As shown in Figure 1, the major algal groups display characteristic structural and functional features that define their biological roles across species.
Figure 1. From structure to function: an overview of major algal groups and species.
2.2 Structural diversity of phlorotannins
As the main polyphenolic compounds in brown algae (orders Laminariales and Fucales) (31), phlorotannins are hydrophilic polymers of phloroglucinol with molecular weights from 126 Da to 650 kDa (32). Their biosynthesis follows the acetate–malonate pathway, initiated by type III polyketide synthase converting acetyl-CoA to malonyl-CoA and culminating in phloroglucinol formation through cyclization and tautomerization. Variations in polymerization degree, linkage patterns, and substituents generate substantial structural diversity, with approximately 150 isomers reported to date (15). For precise structural characterization, nuclear magnetic resonance (NMR) combined with high-resolution mass spectrometry is the optimal approach (33). Low-molecular-weight phlorotannins are classified in Table 1.
Table 1. Structure, distribution and metabolic characteristics of low-molecular-weight brown algal polyphenols.
Brown algal species exhibit substantial variation in phlorotannin content. Extracts from Fucales species range between 145.11 and 275.97 μg PGE/100 mg dry extract, following the order F. serratus > F. guiryi > F. spiralis > F. vesiculosus (34), whereas Sargassum tenerrimum shows a notably high level of 10.00 mg phloroglucinol/g (30). This variability is shaped by multiple factors such as algal morphology, developmental stage, tissue type, and abiotic conditions, such as salinity, light and temperature. Furthermore, a pronounced latitudinal gradient exists: high-latitude populations often contain >4% DW phlorotannins, compared to <2% DW in low-latitude counterparts, suggesting an adaptive response to environmental stimuli (35).
Phlorotannins play essential roles in brown algae growth and survival. They participate in maintaining their cell wall integrity, protecting ultraviolet hurt, and resisting herbivores invasion. Certain phlorotannins are halogenated (bromine/chlorine/iodine) and exhibit a bitter taste while inhibiting digestive enzymes such as amylase and trypsin in grazers. For instance, Fucus increases phlorotannin synthesis in summer, reducing blade grazing by over 40%. In particular, phlorotannins protect against UV-induced damage: under UV stress, soluble phlorotannin levels vary with antioxidant activity, while insoluble pools remain constant (36). This indicates that phlorotannins scavenge free radicals, quench UV-induced ROS, protect photosynthetic enzymes and mitigate oxidative stress, which help brown algae thrive in the intertidal zone environment.
2.3 Unique characteristics of phlorotannins compared with those of terrestrial polyphenols
More than 8,000 structurally distinct polyphenols have been identified from terrestrial plants and marine algae (37). Terrestrial polyphenols mainly come from seeds, roots, bark and stems, and are rich in cocoa, tea, fruits and beans. Their extraction is well-established, and studies have demonstrated their efficacy against metabolic disorders. For instance, rutin can ameliorate gut microbiota dysbiosis in diabetic mice by modulating specific bacterial genera (38, 39). In comparison, marine polyphenols, particularly phlorotannins from brown algae, offer distinct advantages. Their content in seaweeds can be 10–100 times higher than in terrestrial foods (40). The unique interphenyltriol structure (40) exhibites with strong anti-inflammatory activity by inhibiting pro-inflammatory cytokines (41), and can reduce liver fat degeneration by enhancing fatty acid β-oxidation (42). Marine polyphenols are distinguished by their electron-rich structures, which are often functionalized with hydroxyl groups, ether bonds and halogen substituents. This structural signature enhances their ability to scavenge free radicals and bind biological targets (43, 44). Together with their capacity to promote probiotic growth, these attributes highlight considerable promise for use in therapeutics and cosmeceuticals. Nevertheless, practical exploitation remains challenging due to difficulties in reliable sourcing and efficient extraction. As summarized in Table 2, polyphenols from terrestrial and marine sources differ markedly in their structural features, bioactivities, and physiological functions.
Table 2. Comparison of polyphenols from terrestrial and marine sources.
3 Gut microbiota-mediated biotransformation of phlorotannins
3.1 Absorption characteristics of phlorotannins
Bioavailability of phenols refers to the proportion of ingested compounds that reach the systemic circulation to exert biological effects, serving as a key indicator of bioefficacy. Phlorotannins generally exhibit low bioavailability, ranging from 2 to 14% (45). While small-molecule forms are more readily absorbed, their high-molecular-weight counterparts primarily function as a physical UV barrier. However, these macromolecular polymers (often >100 kDa) can be degraded into active fragments. After ingestion, only about 14.1% of Fucus vesiculosus-derived phlorotannins are absorbed in the upper gastrointestinal tract (46), consistent with earlier findings (6). The majority accumulate in the colon, where gut microbiota can metabolize them into absorbable small molecules. This is supported by urinary and plasma metabolite profiling: most phlorotannin metabolites are detected 6–24 h post-consumption, confirming limited small-intestinal absorption and predominant colonic processing (47, 48).
The bioavailability of phlorotannins, which is crucial for their efficacy, is predominantly governed by gut microbiota. A small fraction of low-molecular-weight phlorotannins may be directly absorbed by small intestinal epithelial cells and undergo conjugation in the intestinal mucosa or liver, forming glucuronidated, sulfated, or methylated derivatives that influence their polarity and initial bioavailability (43). However, the majority of these polymers resist upper gastrointestinal absorption and instead transit to the colon, where they are degraded by microbial enzymes, like polyphenol oxidases and hydrolases into smaller phenolic acids (49). These metabolites are modified by host enzymes, including cytochrome P450, glucuronosyltransferases and sulfotransferases in the liver and kidneys before excretion (50). This microbial-centric metabolic pathway is supported by following evidence. For example, seaweed supplementation has been shown to enrich beneficial bacteria such as Shewanella sp. in fish models, improving intestinal barrier function (48). Similarly, the rapid appearance of gallic acid in humans within 2 h post-ingestion suggests efficient hydrolysis by tannin-degrading genera like Lactobacillus and Bifidobacterium (51). Later-stage colonic metabolites, such as 2,3-dihydroxybenzoic acid, may involve hydroxylation by Bacillus or Enterococcus species (25). These findings align with the established role of phenolic compounds in modulating gut microbiota. However, future studies are needed to fully elucidate the specific microbial taxa and enzymatic pathways involved in phlorotannin metabolism. The interaction between brown algal polyphenols and the gut microbiota is summarized in Figure 2.
Figure 2. Interplay between brown algae polyphenols and gut microbiota. Phlorotannins are effectively catabolized by lactic acid bacteria and bifidobacteria into low-molecular-weight metabolites. These microbial derivatives subsequently restructure the gut community by enriching beneficial, short-chain fatty acid producing bacteria and suppressing potential pathogens.
3.2 Biotransformation pathways of phlorotannins
The human gut microbiota exhibits distinct compositional and functional gradients along the gastrointestinal tract. Due to the acidic environment in stomach, the microbial community is relatively sparse; whereas, the large intestine is the main place for microbial colonization and metabolic activities (52). This is also the primary site for the extensive degradation of phlorotannins, a process orchestrated by bacterial enzymes from the gut microbiota. Through a stepwise enzymatic process involving polyphenol esterases and ether bond-cleaving enzymes from genera such as Bacteroides and Lactobacillus, macromolecular phlorotannins are first depolymerized into oligomers like eckol. These are further cleaved into monomers like phloroglucinol by Clostridium and other genera, and finally converted into bioavailable phenolic acids, such as gallic acid and p-hydroxybenzoic acid via dehydroxylases (53).
Together with phlorotannin-stimulated SCFAs, these microbial metabolites form key regulators in host metabolism. This degradative capability represents an evolutionary adaptation to dietary polyphenols. Although phlorotannins possess antibacterial properties due to their phenolic hydroxyl groups, which can disrupt bacterial membranes (54), certain microbiota encodes detoxifying enzymes, including β-glucosidase and O-demethylase, these enzymes not only neutralize the toxicity of phlorotannins but also use them as carbon source, giving these microorganisms a competitive advantage. Consequently, the degradation process rebuilds the gut microbial structure: enriching beneficial degraders and SCFA-producers (Faecalibacterium prausnitzii and Roseburia) while suppressing pathogens. Therefore, elucidating the key degradative pathways will be crucial to clarify the “gut microbiota-metabolites-host” axis and uncover the underlying mechanisms of phlorotannins in modulating health. The metabolic pathways through which phlorotannin-derived metabolites regulate glucose and lipid homeostasis are summarized in Figure 3.
Figure 3. Mechanisms of phlorotannin metabolites in regulating human metabolism. Schematic overview of the role of phlorotannins and their microbial metabolites (PA, GA, PHBA) in glucose and lipid metabolism. Gut microbiota-derived polyphenol oxidases and hydrolases convert phlorotannins into bioactive small molecules. At the hepatic level, these metabolites inhibit gluconeogenesis through AMPK/PEPCK signaling and G6P suppression, while enhancing insulin sensitivity via IRS/PI3K/AKT activation and PTP1B inhibition. In parallel, activation of the Nrf2/HO-1 antioxidant axis reduces reactive oxygen species (ROS) accumulation, thereby alleviating oxidative stress–driven insulin resistance and hepatic lipid peroxidation. In the gut, they attenuate carbohydrate digestion by inhibiting α-glucosidase and α-amylase, and promote a favorable microbiome that produces SCFAs. SCFAs activate GPR43, stimulating lipolysis and energy expenditure. In the pancreas, these metabolites stimulate insulin secretion via the PTP1B/IRS/PI3K/Akt signaling pathway. In adipose tissue, they maintain lipid homeostasis through the SCFAs/GPR43/GLP-1 signaling axis, contributing to glucose and lipid metabolic regulation. Additionally, phlorotannin-associated activation of AMPKα suppresses adipogenic transcription factors C/EBPα and PPARγ, thereby inhibiting adipogenesis and limiting lipid accumulation.
3.3 Comparison of bioactivity between parent phlorotannins and gut-derived metabolites
Research on phlorotannins relies on accurate quantitative analytical methods. Current techniques include spectrophotometric assays, such as the Folin–Ciocalteu method, high-performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR), which provide a reliable basis for the study of metabolic processes of phlorotannins. At the metabolic level, the enzymatic degradation of phlorotannins by the gut microbiota represents a central link in their bioactivity. Specific microbial enzymes decompose macromolecular polyphenols into various of small molecule metabolites These metabolites have pharmacological properties differed from their parent compounds, and are the main active forms of PTs that exerts health benefits. Indeed, the physiological functions of polyphenols are largely determined by these microbially derived bioactive metabolites (55).
The underlied mechanism of this phenomenon is that low-molecular-weight metabolites usually have higher intestinal permeability and bioapailability, so that they can effectively enter the body circulation, reach the target, and give full play to their physiological activity. In contrast, high-molecular-weight polyphenols are difficult to pass through the intestinal barrier and show minimal biovailability (56). It should be noted that interindividual variations in gut microbiota composition directly influence the types and proportions of polyphenol metabolites produced (57). For example, individuals with healthy intestinal flora (rich in beneficial bacteria such as Mycobacterium and Bifidobacterium) are more likely to convert polyphenols into anti-inflammatory compounds, such as procatechic acid (58). On the contrary, in the case of intestinal flora disorder, the metabolic spectrum may turn to prosuce inactive by-products like Phenylpropionic acid. Therefore, to maintain a healthy intestinal microbial ecosystem is crucial to make polyphenol produce highly active, low molecular weight phenolic metabolites, thus, to improve their health benefits. Intervention studies in humans or rats are commonly used to track the metabolic pathways of polyphenols. The analysis of blood, urine and fecal samples after ingestion helps clarify microbiota-derived metabolites and map their pathways and distribution.
Moreover, results from in vitro experiments-such as co-culture of gut microbiota with polyphenols -confirm that the microbial catabolism of phlorotannins not only alters their original bioactivity but also generates highly bioavailable active metabolites (59). Specifically, phlorotannins are primarily degraded into low-molecular-weight metabolites such as phenolic acids and SCFAs. The metabolites exhibit higher bioavailability than their native precursors and exert more potent regulatory effects on host metabolism. For instance, gallic acid helps modulate blood glucose by inhibiting hepatic gluconeogenesis (60). Meanwhile, SCFAs activate intestinal receptors GPR43 and GPR41, which promote lipid breakdown and help maintain body weight and lipid balance (61). Notably, besides phlorotannins, other brown algae-derived compounds such as alginate and fucoxanthin also exhibit substantial physiological activity (62). Studies indicate that all three components effectively inhibit lipase activity, suggesting a complementary role in reducing dietary fat digestion and absorption.
3.4 Potential synergistic effects between phlorotannins and other bioactive compounds
In brown seaweeds, phlorotannins inherently co-occur with algal polysaccharides (6), particularly alginates and fucoidans, as well as dietary fibers (63) and minor bioactive compounds (64). Alginates are linear polysaccharides primarily composed of mannuronic acid and guluronic acid units (65). Alginates play a key role in the structural integrity of the cell walls. Fucoidan is a sulfated polysaccharide mainly composed of fucose along with other sugars like galactose, xylose, and mannose. It is known for its immune-modulating, anti-coagulant, and anti-inflammatory properties (66). Phlorotannins and alginates are commonly present together in the cell walls of brown algae, forming a complex network of bioactive compounds that interact with each other. These interactions are primarily due to the chemical nature of these components, where phlorotannins, as strong antioxidants, can form high molecular weight complexes with alginates under the action of oxidative enzymes (67).
Several biochemical and structural studies have indicated that (68), phlorotannins can undergo oxidative cross-linking with polysaccharides such as alginates to form high-molecular-weight complexes, thereby modulating the sequestration and release of bioactive compounds. This physicochemical association represents an intrinsic form of synergistic interaction between phlorotannins and algal polysaccharides. Similarly, phlorotannins and alginate likely suppressed microbial activity, thereby slowing the increase in pH. Consistent with this notion, a recent study demonstrated that a phlorotannin–alginate combination from brown algae synergistically inhibited polyphenol oxidase activity, with 2% phlorotannins + 1% alginate achieving the highest inhibition (84.51%), comparable to 1% ascorbic acid (72.43%), and effectively delayed melanosis and overall quality deterioration in ice-stored Pacific white shrimp (69).
These complexes enhance the stability and bioavailability of the compounds, potentially affecting nutrient absorption, metabolism, and immune modulation. For instance, alginates and fucoidans are known to modulate gut microbiota and promote short-chain fatty acid production (70), while phlorotannins contribute by further enhancing these effects through antioxidant and anti-inflammatory mechanisms. The combined action of these compounds may regulate various metabolic processes, such as lipid and glucose metabolism, by improving gut barrier function, modulating gut microbiota composition, and enhancing nutrient absorption (71).
4 Mechanisms underlying the regulation of host metabolism by phlorotannins via the gut microbiota
Phlorotannins directly modulate metabolic processes by targeting key enzymes and pathways involved in glucose and lipid homeostasis. In carbohydrate metabolism, they inhibit α-glucosidase and α-amylase (72), which slows down carbohydrate digestion and postprandial glucose absorption. They also suppress protein tyrosine phosphatase 1B (PTP1B) activity, thereby enhancing insulin signaling and sensitivity (73). They also downregulate the expression of liver enzymes involved in gluconeogenesis, such as glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), while increasing the activity of glucokinase (GK), thus promoting glucose utilization and storage. Based on mouse and zebrafish models in lipid metabolism, Dieckol could activate AMPKα signaling to suppress lipid accumulation (74). Other compounds, such as those derived from Eucalyptus cavaleriei, Crepidotus applanatus, and Ishige okamurae, similarly inhibit adipogenesis by downregulating C/EBPα and PPARγ and inducing preadipocyte apoptosis (75). Taken together, these findings underscore the established role of phlorotannins in regulating metabolism.
Since gut microbiota was first identified in host energy homeostasis in 2004 (76), its contribution to metabolic regulation has been widely recognized. Phlorotannins are poorly absorbed in the upper digestive tract, and rely heavily on microbial transformation to produce bioavailable metabolites such as GA and PHBA. Beneficial bacteria including Bifidobacterium and Bacteroides are primarily responsible for this conversion. And phlorotannins modulate gut microbial composition in return; for instance, Sargassum polyphenol extracts inhibit biofilm formation in opportunistic pathogens like Escherichia coli and Pseudomonas aeruginosa (77), thereby promoting microbial balance and facilitating efficient phlorotannin transformation.
The following sections will focus on how the small molecule metabolites of phlorotannins affect host metabolism and interact with gut microbial community.
4.1 Regulation of glucose metabolism
In vitro studies have demonstrated that a specific phlorotannin extract dose dependently inhibits α-amylase and α-glucosidase. Consistent with these results, animal studies have shown that the same extract can reduce postprandial blood glucose peaks by 90% and insulin secretion peaks by 40%. These results collectively confirm the efficacy of this extract in modulating carbohydrate digestion and absorption, supporting its potential application in functional foods or dietary supplements (78). Besides, a systematic review identified consistent inverse associations between certain gut bacteria and glucose metabolism, including Akkermansia muciniphila, Bifidobacterium longum, Faecalibacterium, the Clostridium leptum group, and Faecalibacterium prausnitzii (79). Increased abundance of these microbial communities was associated with improved glucose metabolism and insulin sensitivity. In summary, these findings suggest that fluorotannins can improve glucose metabolism by regulating gut microbiota. This proposed mechanism involves the enrichment of beneficial bacterial taxa alongside the suppression of harmful species, thereby establishing a synergistic “phlorotannin-gut microbiota-glucose metabolism” axis.
4.2 Regulation of lipid metabolism
SCFAs mainly come from the microbial fermentation of dietary fiber, including acetic acid (about 60%), propionic acid (about 25%) and butyric acid (about 15%). They are the primary energy sources of colon cells and play crucial roles in intestinal health, immunomodulation and microbial ecology (80).
Dietary polyphenols, including catechins and anthocyanins, are known to enhance SCFA production. Similarly, phlorotannins from brown algae such as Fucus vesiculosus significantly elevate propionate and butyrate levels. Some extracts can also promote the growth of Bifidobacterium, of which can produce acetic acid and activate PPAR-α pathway, thus to enhance β-oxidation of fatty acids in the liver and reduce blood triglyceride levels (81, 82). Given the variable effects of different algal extracts, advancing purification techniques is an imperative for future study.
Beyond SCFAs, phlorotannin metabolites such as GA also ameliorate metabolic disorders. In mouse models of steatohepatitis (MASH), GA accelerated lipid metabolism via IRF6-mediated suppression of PPARγ, and directly activated AMPKα to alleviate NAFLD progression (83). Phlorotannins could also modulate gut microbiota structure by lowering the Firmicutes/Bacteroidetes ratio, which is often found elevated in obesity. Besides, Bacteroidetes further metabolize polyphenols into bioactive metabolites that improve cholesterol homeostasis (84, 85).
In summary, phlorotannins regulate lipid metabolism based on the gut microbiota by modulating microbial composition, promoting beneficial metabolites, like SCFAs and GA, as well as targeting key signaling nodes such as AMPK and PPARα. These mechanisms underscore their potential role in preventing and treating metabolic disorders such as obesity, NAFLD, and dyslipidemia.
5 Phlorotannins and their metabolic pathways: from intake to target interaction
Early human and in vitro studies have demonstrated that phlorotannins are extensively metabolized by colonic microbiota, resulting in the production of low-molecular-weight phenolic derivatives, which are detectable in urine and plasma (50). This highlights the crucial role of microbial transformation in their bioavailability and bioactivity. In line with this, in vitro gastrointestinal digestion and fermentation models have shown significant degradation of phlorotannin extracts during simulated digestion and colonic fermentation, further emphasizing the involvement of both digestive enzymes and gut microbial enzymes in phlorotannin metabolism (48). These transformations contribute not only to the release of bioactive metabolites but also to the modulation of gut microbiota composition. Specifically, brown seaweed extracts rich in phlorotannins have been found to promote the growth of beneficial bacteria such as Bifidobacterium and Lactobacillus (86), while simultaneously increasing short-chain fatty acid production during colonic fermentation. This suggests a metabolic cross-talk between phlorotannins and the gut microbiota. Recent reviews also confirm that oral phlorotannins undergo biochemical transformations mediated by digestive and gut microbial enzymes, including hydrolytic cleavage and reductive metabolism, which play a key role in their absorption and systemic effects.
To fully understand the metabolic effects of phlorotannins, it is crucial to investigate their entire journey from intake to target interaction. The process begins with phlorotannin ingestion, followed by microbial transformation in the gut, where gut microbiota break down complex polyphenols into bioavailable metabolites. These metabolites are then distributed throughout the body, reaching target organs like the liver, adipose tissue, and muscles, where they exert their regulatory effects on glucose and lipid metabolism. The final stage involves target interactions, where these metabolites influence key metabolic pathways, such as insulin signaling and lipid oxidation. The Table 3 below provides a clear overview of this process, helping to clarify the complex role of phlorotannins in metabolic regulation.
Table 3. A sequential process of intake, microbial transformation, metabolite distribution, and target interaction.
6 Clinical evidence and translational potential of phlorotannins in metabolic disorders
6.1 Preclinical and clinical studies
Diabetes is a metabolic disorder characterized by elevated blood glucose levels. One effective treatment is to inhibit enzymes responsible for carbohydrate digestion, thereby reducing postprandial blood glucose level (87). In this context, extracts from brown algae such as Undaria pinnatifida have shown promise. In vivo studies demonstrate that U. pinnatifida extract lowers fasting blood glucose in diabetic mice by modulating key genes, including upregulating Pi3k, Glut4, Akt, and Ampk while downregulating Foxo1, Pgc-1α, Gsk-3β, and G6pc (42).
Different brown algal extracts appear to inhibit α-glucosidase through distinct mechanisms, depending on their composition and molecular weight profile (88). For instance, Laminaria japonica extract acts as an effective α-glucosidase inhibitor, potentially limiting intestinal monosaccharide release (89). Network pharmacology analyses further suggest that phlorotannins may target multiple proteins implicated in type 2 diabetes, such as BACE1, AKT1, ESR1 to regulate glucose metabolism (90). Clinically, a meta-analysis confirmed that brown algae supplementation significantly improves glycemic control, reducing postprandial glucose, HbA1c, and HOMA-IR, with higher doses (≥1,000 mg) conferring greater benefits (91). In addition, a double-blind randomized trial found no sex-specific differences in the glucose-lowering roles of phlorotannins (92).
To date, several randomized controlled trials (RCTs) have explored the dose–effect relationship of phlorotannins in the regulation of glycolipid metabolism in humans, providing preliminary evidence for effective dose ranges and safety margins. In a double-blind RCT involving individuals with prediabetes, a single oral dose of 600 mg Ecklonia cava extract (containing approximately 13% phlorotannic polyphenols) significantly attenuated postprandial glucose responses without reported adverse effects (93). According to safety evaluations summarized by the European Food Safety Authority (EFSA), daily intakes of E. cava phlorotannins up to 263 mg in adults (163 mg/day for adolescents aged 12–14 years; 230 mg/day for adolescents >14 years) are considered safe when used as dietary supplements (94). Within this regulatory range, a 12-week randomized controlled trial in 97 overweight adults demonstrated that supplementation with E. cava polyphenol extract at doses of 72 mg or 144 mg/day significantly reduced total cholesterol, LDL-C, and the total cholesterol/HDL-C ratio in a dose-dependent manner (95). Similarly, a 12-week randomized controlled trial in patients with hyperlipidemia showed that daily supplementation with 400 mg of a polyphenol-rich Ecklonia cava extract produced comparable lipid-lowering effects (96). From a safety perspective, E. cava phlorotannins have a long history of use as food supplements. In the United States, supplements containing E. cava phlorotannins have been marketed since 2006, typically providing approximately 100 mg/day (94). Although concerns have been raised regarding iodine content in brown algae extracts—particularly for individuals at high risk of thyroid dysfunction—no direct toxic effects attributable to phlorotannins themselves have been reported to date.
Taken together, current evidence suggests that the metabolic effects of phlorotannins are dose-dependent but context-specific (48), influenced by extract composition, dosing duration, baseline metabolic status, and population characteristics. While effective and safe dose ranges have been proposed for adults and adolescents, inconsistencies across studies underscore the need for larger, well-controlled clinical trials employing standardized phlorotannin preparations and multiple dose levels. Such studies will be essential to refine the optimal dose window, clarify inter-individual variability, and support the clinical translation of phlorotannins for glycolipid metabolic regulation.
6.2 Translational challenges in clinical application
Growing evidence support the beneficial role of phlorotannins in modulating glucose and lipid metabolism. Although PTs was discovered nearly 50 years ago (1978) (97), there are still key gaps in metabolomics mechanism, large-scale clinical verification and comprehensive safety, which hinders their large-scale production and clinical transformation.
Current research on phlorotannins suffers from limitations. Most studies merely document phenotypic improvements in metabolic parameters, like blood glucose and lipids level, but lack mechanistic depth. In addition, as the comparative data is limited, the potential benefits of combination regimens have not been studied. More critically, the fundamental differences in the liver enzyme system and renal excretory function various from species make it impossible to direct animal experimental data into humans. Additionally, animal models of metabolic diseases are typically artificially constructed with single etiologies (6), whereas human metabolic disorders naturally present with multiple comorbidities, such as hypertension, insulin resistance, and inflammatory responses, which involves far more complex pathological mechanisms.
Consequently, systematic clinical research has become an indispensable prerequisite for the clinical application of phlorotannins. Besides, formulation development represents another critical bottleneck. While most animal studies use crude extracts or highly purified monomers, human applications require pharmaceutical-grade formulations. Phlorotannins exhibit poor stability under environmental conditions such as temperature and pH variations, coupled with low water solubility and susceptibility to enzymatic degradation in vivo, resulting in suboptimal bioavailability (92). These challenges demand process optimization, including the selection of appropriate excipients, refinement of preparation methods to enhance stability, and the adoption of advanced delivery technologies such as ultrasound-assisted extraction (USAE) (98), microspheres, hydrogels, and nanoparticle-based systems (99) to improve solubility and in vivo delivery efficiency.
Bridging the gap between promise and clinical practice requires future research to overcome challenges in mechanism elucidation, clinical validation, and formulation science, ultimately confirming phlorotannins as a viable adjunct therapy.
7 Current research gaps and future perspectives
Marine organisms are a rich source of diverse phenolic compounds, among which phlorotannins have gained increasing research interest due to their unique chemical structures and potential to modulate gut microbiota and host metabolism. However, in order to accelerate its clinic application, some research gaps still need to be solved.
First of all, the metabolic role of phlorotannins compounds in different individuals are not yet clear; for example, health population, patients with prediabetes or diabetics. It is unclear whether their influence on gut microbiota or metabolic pathways differs according to host characteristics or disease stage. In addition, the long-term safety profile of phlorotannins have not been systematically established. Most studies use single doses or narrow doses range, which make cumulative effects of long-term intake on metabolic homeostasis unclear. A further limitation is the scarcity of publicly available intervention-based metabolomics datasets (in humans or animals) following phlorotannin supplementation. This gap constrains systematic mapping of in vivo biotransformation products, tissue distribution patterns, and downstream pathway engagement, thereby limiting evidence-weighted identification of novel targets for Figure-level mechanistic integration.
A major translational challenge lies in the low bioavailability of phlorotannins (100). These compounds are prone to degradation under environmental and gastrointestinal conditions, and their large molecular size limits intestinal absorption. Although the newly delivery system and improved extraction methods show the improved stability and accuracy, most of them are lack clinical verification.
From an application standpoint, phlorotannins are typically consumed indirectly through dietary brown algae, and there is no standardized or collaborative application at present. Besides, there is limited research on its combined effect with dietary fiber, probiotics or other bioactive ingredients, and individual variations in gut microbiota composition further complicate consistent efficacy.
In summary, future research should prioritize elucidating specific effects, establishing dose response and long-term safety data, advancing delivery technologies, clarifying functional distinctions from other polyphenols, and developing synergistic or personalized application frameworks to fully realize the potential of phlorotannins in metabolic health.
8 Conclusion
In summary, phlorotannins compounds represent a promising field in marine natural product research, and increasing evidence shows that they play an important role in regulating intestinal flora and human metabolism. Although their potential is considerable, this review also reveals significant knowledge gaps that must be addressed to unlock their translational value. Future efforts should leverage advanced analytical and multi-omics technologies to fully elucidate their mechanisms, biotechnological applications and ecological roles.
Author contributions
SW: Writing – original draft. ZS: Writing – review & editing. JP: Investigation, Writing – review & editing. XM: Data curation, Writing – review & editing. XL: Resources, Writing – original draft. DX: Visualization, Writing – review & editing. QM: Methodology, Data curation, Investigation, Writing – review & editing. XH: Conceptualization, Project administration, Writing – original draft. YS: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was funded by the National Natural Science Foundation of China 82400292 to YS, Zhejiang Provincial Natural Science Foundation Joint Fund Project/Key Project to JP (grant number LHDMZ24H070001).
Conflict of interest
XM was employed by Qingdao Mingyue Seaweed Group Co.Ltd.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Islam, ANMS, Sultana, H, Refat, NH, Farhana, Z, Abdulbasah Kamil, A, and Meshbahur Rahman, M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: a meta-analysis. Prev Med Rep. (2024) 46:102882. doi: 10.1016/j.pmedr.2024.102882
2. Dimitrova, D, Kehayova, G, Dimitrova, S, and Dragomanova, S. Marine-derived natural substances with anticholinesterase activity. Mar Drugs. (2025) 23:439. doi: 10.3390/md23110439,
3. Lu, X, Xie, Q, Pan, X, Zhang, R, Zhang, X, Peng, G, et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther. (2024) 9:262. doi: 10.1038/s41392-024-01951-9
4. ElSayed, NA, Aleppo, G, Aroda, VR, Bannuru, RR, Brown, FM, Bruemmer, D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care. (2023) 46:S19–40. doi: 10.2337/dc23-S002,
5. Xu, S, Qin, Z, Yuan, R, Cui, X, Zhang, L, Bai, J, et al. The hemoglobin glycation index predicts the risk of adverse cardiovascular events in coronary heart disease patients with type 2 diabetes mellitus. Front Cardiovasc Med. (2022) 9:992252. doi: 10.3389/fcvm.2022.992252
6. López-Cárdenas, FG, Mateos, R, Sánchez-Burgos, JA, Zamora-Gasga, VM, Blancas-Benítez, FJ, González-Cordova, AF, et al. In vitro gastrointestinal digestion of phlorotannins from Ulva lactuca: Nutritional value and implications in disease mechanisms through pharmacology network. Food Res Int. (2025) 204:115928. doi: 10.1016/j.foodres.2025.115928,
7. Catarino, MD, Silva, A, Cruz, MT, Mateus, N, Silva, AM, and Cardoso, SM. Phlorotannins from Fucus vesiculosus: modulation of inflammatory response by blocking NF-κB signaling pathway. Int J Mol Sci. (2020) 21:6897. doi: 10.3390/ijms21186897
8. Herath, KHINM, Nagahawatta, DP, Wang, L, and Sanjeewa, KKA. The role of phlorotannins to treat inflammatory diseases. Chemistry. (2025) 7:77. doi: 10.3390/chemistry7030077
9. Ahn, JH, Yang, YI, Lee, KT, and Choi, JH. Dieckol, isolated from the edible brown algae Ecklonia cava, induces apoptosis of ovarian cancer cells and inhibits tumor xenograft growth. J Cancer Res Clin Oncol. (2015) 141:255–68. doi: 10.1007/s00432-014-1819-8,
10. Seca, AML, and Pinto, DCGA. Overview on the antihypertensive and anti-obesity effects of secondary metabolites from seaweeds. Mar Drugs. (2018) 16:237. doi: 10.3390/md16070237
11. Li, C, Du, L, Xiao, Y, Fan, L, Li, Q, and Cao, CY. Multi-active phlorotannins boost antimicrobial peptide LL-37 to promote periodontal tissue regeneration in diabetic periodontitis. Mater Today Bio. (2025) 31:101535. doi: 10.1016/j.mtbio.2025.101535
12. Park, JS, Han, JM, Shin, YN, Park, YS, Shin, YR, Park, SW, et al. Exploring bioactive compounds in brown seaweeds using subcritical water: a comprehensive analysis. Mar Drugs. (2023) 21:328. doi: 10.3390/md21060328
13. Cosme, F, Aires, A, Pinto, T, Oliveira, I, Vilela, A, and Gonçalves, B. A comprehensive review of bioactive tannins in foods and beverages: functional properties, health benefits, and sensory qualities. Molecules. (2025) 30:800. doi: 10.3390/molecules30040800
14. Catarino, MD, Silva, AMS, Mateus, N, and Cardoso, SM. Optimization of phlorotannins extraction from Fucus vesiculosus and evaluation of their potential to prevent metabolic disorders. Mar Drugs. (2019) 17:162. doi: 10.3390/md17030162
15. Fernando, IPS, Lee, W, and Ahn, G. Marine algal flavonoids and phlorotannins; an intriguing frontier of biofunctional secondary metabolites. Crit Rev Biotechnol. (2022) 42:23–45. doi: 10.1080/07388551.2021.1922351
16. Xie, F, Yang, W, Xing, M, Zhang, H, and Ai, L. Natural polyphenols-gut microbiota interactions and effects on glycolipid metabolism via polyphenols-gut-brain axis: a state-of-the-art review. Trends Food Sci Technol. (2023) 140:104171. doi: 10.1016/j.tifs.2023.104171
17. Hou, K, Wu, ZX, Chen, XY, Wang, JQ, Zhang, D, Xiao, C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. (2022) 7:135. doi: 10.1038/s41392-022-00974-4,
18. Corbin, KD, Igudesman, D, Smith, SR, Zengler, K, and Krajmalnik-Brown, R. Targeting the Gut Microbiota’s Role in Host Energy Absorption With Precision Nutrition Interventions for the Prevention and Treatment of Obesity. Nutr Rev. (2025) 83:1928–43. doi: 10.1093/nutrit/nuaf046,
19. Pradhan, B, Bhuyan, PP, Patra, S, Nayak, R, Behera, PK, Behera, C, et al. Beneficial effects of seaweeds and seaweed-derived bioactive compounds: current evidence and future prospective. Biocatal Agric Biotechnol. (2022) 39:102242. doi: 10.1016/j.bcab.2021.102242
20. Ismail, MM, El Zokm, GM, and Miranda Lopez, JM. Nutritional, bioactive compounds content, and antioxidant activity of brown seaweeds from the Red Sea. Front Nutr. (2023) 10:1210934. doi: 10.3389/fnut.2023.1210934
21. Keleszade, E, Patterson, M, Trangmar, S, Guinan, KJ, and Costabile, A. Clinical efficacy of brown seaweeds Ascophyllum nodosum and Fucus vesiculosus in the prevention or delay progression of the metabolic syndrome: a review of clinical trials. Molecules. (2021) 26:714. doi: 10.3390/molecules26030714,
22. Lopes, G, Barbosa, M, Vallejo, F, Gil-Izquierdo, Á, Andrade, PB, Valentão, P, et al. Profiling phlorotannins from Fucus spp. of the Northern Portuguese coastline: chemical approach by HPLC-DAD-ESI/MSn and UPLC-ESI-QTOF/MS. Algal Res. (2018) 29:113–20. doi: 10.1016/j.algal.2017.11.025
23. Suryaningtyas, IT, Lee, DS, and Je, JY. Brown algae Ecklonia cava extract modulates adipogenesis and browning in 3T3-L1 preadipocytes through HO-1/Nrf2 signaling. Mar Drugs. (2024) 22:330. doi: 10.3390/md22080330
24. Ferreira, CAM, Félix, R, Félix, C, Januário, AP, Alves, N, Novais, SC, et al. A biorefinery approach to the biomass of the seaweed Undaria pinnatifida (Harvey Suringar, 1873): obtaining phlorotannins-enriched extracts for wound healing. Biomolecules. (2021) 11:461. doi: 10.3390/biom11030461
25. Barbosa, M, Valentão, P, and Andrade, PB. Polyphenols from brown seaweeds (Ochrophyta, Phaeophyceae): phlorotannins in the pursuit of natural alternatives to tackle neurodegeneration. Mar Drugs. (2020) 18:654. doi: 10.3390/md18120654
26. Wijesinghe, WAJP, and Jeon, YJ. Biological activities and potential cosmeceutical applications of bioactive components from brown seaweeds: a review. Phytochem Rev. (2011) 10:431–43. doi: 10.1007/s11101-011-9214-4
27. Gómez-Guzmán, M, Rodríguez-Nogales, A, Algieri, F, and Gálvez, J. Potential Role of Seaweed Polyphenols in Cardiovascular-Associated Disorders. Mar Drugs. (2018) 16:250. doi: 10.3390/md16080250
28. Catarino, MD, Pires, SMG, Silva, S, Costa, F, Braga, SS, Pinto, DCGA, et al. Overview of phlorotannins’ constituents in Fucales. Mar Drugs. (2022) 20:754. doi: 10.3390/md20120754,
29. Phenolic compounds and antioxidant activities of selected species of seaweeds from Danish coast. Food Chem. (2013) 138:1670–81. doi: 10.1016/j.foodchem.2012.10.078,
30. Steevensz, AJ, MacKinnon, SL, Hankinson, R, Craft, C, Connan, S, Stengel, DB, et al. Profiling phlorotannins in brown macroalgae by liquid chromatography-high resolution mass spectrometry. Phytochem Anal. (2012) 23:547–53. doi: 10.1002/pca.2354
31. Lima, EMF, Bueris, V, Germano, LG, Sircili, MP, and Pinto, UM. Synergistic effect of the combination of phenolic compounds and tobramycin on the inhibition of Pseudomonas aeruginosa biofilm. Microb Pathog. (2024) 197:107079. doi: 10.1016/j.micpath.2024.107079
32. Bouafir, Y, Bouhenna, MM, Nebbak, A, Belfarhi, L, Aouzal, B, Boufahja, F, et al. Algal bioactive compounds: a review on their characteristics and medicinal properties. Fitoterapia. (2025) 183:106591. doi: 10.1016/j.fitote.2025.106591
33. Isaza Martínez, JH, and Torres Castañeda, HG. Preparation and Chromatographic Analysis of Phlorotannins. J Chromatogr Sci. (2013) 51:825–38. doi: 10.1093/chromsci/bmt045,
34. Sharifian, S, Shabanpour, B, Taheri, A, and Kordjazi, M. Effect of phlorotannins on melanosis and quality changes of Pacific white shrimp (Litopenaeus vannamei) during iced storage. Food Chem. (2019) 298:124980. doi: 10.1016/j.foodchem.2019.124980
35. Mannion, PD. A deep-time perspective on the latitudinal diversity gradient. Proc Natl Acad Sci USA. (2020) 117:17479–81. doi: 10.1073/pnas.2011997117,
36. Cruces, E, Huovinen, P, and Gómez, I. Phlorotannin and antioxidant responses upon short-term exposure to UV radiation and elevated temperature in three south Pacific kelps. Photochem Photobiol. (2012) 88:58–66. doi: 10.1111/j.1751-1097.2011.01013.x
37. El-Saadony, MT, Yang, T, Saad, AM, Alkafaas, SS, Elkafas, SS, Eldeeb, GS, et al. Polyphenols: chemistry, bioavailability, bioactivity, nutritional aspects and human health benefits: a review. Int J Biol Macromol. (2024) 277:134223. doi: 10.1016/j.ijbiomac.2024.134223
38. Cai, C, Cheng, W, Shi, T, Liao, Y, Zhou, M, and Liao, Z. Rutin alleviates colon lesions and regulates gut microbiota in diabetic mice. Sci Rep. (2023) 13:1–13. doi: 10.1038/s41598-023-31647-z
39. Rupérez, P, Ahrazem, O, and Leal, JA. Potential antioxidant capacity of sulfated polysaccharides from the edible marine brown seaweed Fucus vesiculosus. J Agric Food Chem. (2002) 50:840–5. doi: 10.1021/jf010908o
40. Zheng, H, Zhao, Y, and Guo, L. A bioactive substance derived from brown seaweeds: phlorotannins. Mar Drugs. (2022) 20:742. doi: 10.3390/md20120742
41. Khan, F, Jeong, GJ, Khan, MSA, Tabassum, N, and Kim, YM. Seaweed-derived phlorotannins: a review of multiple biological roles and action mechanisms. Mar Drugs. (2022) 20:384. doi: 10.3390/md20060384
42. Liu, Y, Zhang, D, Liu, GM, Chen, Q, and Lu, Z. Ameliorative effect of dieckol-enriched extraction from Laminaria japonica on hepatic steatosis induced by a high-fat diet via β-oxidation pathway in ICR mice. J Funct Foods. (2019) 58:44–55. doi: 10.1016/j.jff.2019.04.051
43. Meng, W, Mu, T, Sun, H, and Garcia-Vaquero, M. Phlorotannins: a review of extraction methods, structural characteristics, bioactivities, bioavailability, and future trends. Algal Res. (2021) 60:102484. doi: 10.1016/j.algal.2021.102484
44. Balboa, EM, Conde, E, Moure, A, Falqué, E, and Domínguez, H. In vitro antioxidant properties of crude extracts and compounds from brown algae. Food Chem. (2013) 138:1764–85. doi: 10.1016/j.foodchem.2012.11.026,
45. Drygalski, K, Fereniec, E, Zalewska, A, Krętowski, A, Żendzian-Piotrowska, M, and Maciejczyk, M. Phloroglucinol prevents albumin glycation as well as diminishes ROS production, glycooxidative damage, nitrosative stress and inflammation in hepatocytes treated with high glucose. Biomed Pharmacother. (2021) 142:111958. doi: 10.1016/j.biopha.2021.111958
46. Cassani, L, Gomez-Zavaglia, A, Jimenez-Lopez, C, Lourenço-Lopes, C, Prieto, MA, and Simal-Gandara, J. Seaweed-based natural ingredients: stability of phlorotannins during extraction, storage, passage through the gastrointestinal tract and potential incorporation into functional foods. Food Res Int. (2020) 137:109676. doi: 10.1016/j.foodres.2020.109676
47. Zhang, H, and Tsao, R. Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects. Curr Opin Food Sci. (2016) 8:33–42. doi: 10.1016/j.cofs.2016.02.002
48. Corona, G, Ji, Y, Anegboonlap, P, Hotchkiss, S, Gill, C, Yaqoob, P, et al. Gastrointestinal modifications and bioavailability of brown seaweed phlorotannins and effects on inflammatory markers. Br J Nutr. (2016) 115:1240–53. doi: 10.1017/S0007114516000210,
49. Zhang, Z, Li, X, Sang, S, McClements, DJ, Chen, L, Long, J, et al. Polyphenols as plant-based nutraceuticals: health effects, encapsulation, nano-delivery, and application. Foods Basel Switz. (2022) 11:2189. doi: 10.3390/foods11152189
50. Rodriguez-Mateos, A, Rendeiro, C, Bergillos-Meca, T, Tabatabaee, S, George, TW, Heiss, C, et al. Intake and time dependence of blueberry flavonoid-induced improvements in vascular function: a randomized, controlled, double-blind, crossover intervention study with mechanistic insights into biological activity. Am J Clin Nutr. (2013) 98:1179–91. doi: 10.3945/ajcn.113.066639,
51. Ebrahimi, F, Subbiah, V, Agar, OT, Legione, AR, and Suleria, HAR. Site-specific impact of polyphenols on the gastrointestinal microbiome. Crit Rev Food Sci Nutr. (2025) 65:5971–94. doi: 10.1080/10408398.2024.2434961,
52. Johnson, TG, and Langton, MJ. Molecular Machines For The Control Of Transmembrane Transport. J Am Chem Soc. (2023) 145:27167–84. doi: 10.1021/jacs.3c08877,
53. Zhou, Y, Wei, Y, Jiang, L, Jiao, X, and Zhang, Y. Anaerobic phloroglucinol degradation by Clostridium scatologenes. MBio. (2023) 14:e0109923. doi: 10.1128/mbio.01099-23,
54. Vaga, S, Lee, S, Ji, B, Andreasson, A, Talley, NJ, Agréus, L, et al. Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals. Sci Rep. (2020) 10:14977. doi: 10.1038/s41598-020-71939-2,
55. Lemesheva, V, Islamova, R, Stepchenkova, E, Shenfeld, A, Birkemeyer, C, and Tarakhovskaya, E. Antibacterial, antifungal and algicidal activity of phlorotannins, as principal biologically active components of ten species of brown algae. Plants. (2023) 12:821. doi: 10.3390/plants12040821
56. Scott, MB, Styring, AK, and McCullagh, JSO. Polyphenols: bioavailability, microbiome interactions and cellular effects on health in humans and animals. Pathogens. (2022) 11:770. doi: 10.3390/pathogens11070770
57. Procházková, N, Laursen, MF, La Barbera, G, Tsekitsidi, E, Jørgensen, MS, Rasmussen, MA, et al. Gut physiology and environment explain variations in human gut microbiome composition and metabolism. Nat Microbiol. (2024) 9:3210–25. doi: 10.1038/s41564-024-01856-x
58. Bresser, LRF, de Goffau, MC, Levin, E, and Nieuwdorp, M. Gut microbiota in nutrition and health with a special focus on specific bacterial clusters. Cells. (2022) 11:3091. doi: 10.3390/cells11193091
59. Wan, MLY, Co, VA, and El-Nezami, H. Dietary polyphenol impact on gut health and microbiota. Crit Rev Food Sci Nutr. (2021) 61:690–711. doi: 10.1080/10408398.2020.1744512,
60. Lee, AT, Yang, MY, Lee, YJ, Yang, TW, Wang, CC, and Wang, CJ. Gallic acid improves diabetic steatosis by downregulating MicroRNA-34a-5p through targeting NFE2L2 expression in high-fat diet-fed db/db mice. Antioxid Basel Switz. (2021) 11:92. doi: 10.3390/antiox11010092
61. Lee, DH, Kim, MT, and Han, JH. GPR41 and GPR43: from development to metabolic regulation. Biomed Pharmacother. (2024) 175:116735. doi: 10.1016/j.biopha.2024.116735
62. Phang, SJ, Teh, HX, Looi, ML, Arumugam, B, Fauzi, MB, and Kuppusamy, UR. Phlorotannins from brown algae: a review on their antioxidant mechanisms and applications in oxidative stress-mediated diseases. J Appl Phycol. (2023) 35:867–92. doi: 10.1007/s10811-023-02913-4
63. Silva, A, Cassani, L, Grosso, C, Garcia-Oliveira, P, Morais, SL, Echave, J, et al. Recent advances in biological properties of brown algae-derived compounds for nutraceutical applications. Crit Rev Food Sci Nutr. (2024) 64:1283–311. doi: 10.1080/10408398.2022.2115004,
64. Praveen, M. A., Yu, L., Selva, C., and Bulone, V. Optimization of ultrasound-assisted natural deep eutectic solvent extraction for the recovery of bioactive polysaccharides and phlorotannins from the brown alga Ecklonia radiata. Int J Biol Macromol 2025;338(Pt:149744, doi: 10.1016/j.ijbiomac.2025.149744.
65. Frazzini, S, and Rossi, L. Anticancer properties of macroalgae: a comprehensive review. Mar Drugs. (2025) 23:70. doi: 10.3390/md23020070
66. Jeong, S, Lee, S, Lee, G, Hyun, J, and Ryu, B. Systematic characteristics of fucoidan: intriguing features for new pharmacological interventions. Int J Mol Sci. (2024) 25:11771. doi: 10.3390/ijms252111771
67. Zhang, J, Xing, L, Meng, W, Zhang, X, Li, J, and Dong, P. Molecular weight distribution and structure analysis of phlorotannins in Sanhai kelp (Saccharina japonica) and evaluation of their antioxidant activities. Food Chem. (2025) 469:142569. doi: 10.1016/j.foodchem.2024.142569
68. Duan, X, Agar, OT, Barrow, CJ, Dunshea, FR, and Suleria, HAR. Improving potential strategies for biological activities of phlorotannins derived from seaweeds. Crit Rev Food Sci Nutr. (2025) 65:833–55. doi: 10.1080/10408398.2023.2282669,
69. Sharifian, S, and Bita, S. Phlorotannin-alginate extract from Nizimuddinia zanardinii for melanosis inhibition and quality preservation of Pacific white shrimp. Foods Basel Switz. (2025) 14:3736. doi: 10.3390/foods14213736
70. Ahmad, A, Riaz, S, and Desta, DT. Alginate’s ability to prevent metabolic illnesses, the degradation of the gut’s protective layer, and alginate-based encapsulation methods. Food Sci Nutr. (2024) 12:8692–714. doi: 10.1002/fsn3.4455,
71. Fan, Y, Liu, Y, Shao, C, Jiang, C, Wu, L, Xiao, J, et al. Gut microbiota-targeted therapeutics for metabolic disorders: mechanistic insights into the synergy of probiotic-fermented herbal bioactives. Int J Mol Sci. (2025) 26:5486. doi: 10.3390/ijms26125486,
72. Pizzi, A. Tannins medical / pharmacological and related applications: A critical review. Sustain Chem Pharm. (2021) 22:100481. doi: 10.1016/j.scp.2021.100481
73. Carmody, RN, and Turnbaugh, PJ. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest. (2014) 124:4173–81. doi: 10.1172/JCI72335,
74. Ćorković, I, Gašo-Sokač, D, Pichler, A, Šimunović, J, and Kopjar, M. Dietary polyphenols as natural inhibitors of α-amylase and α-glucosidase. Life Basel Switz. (2022) 12:1692. doi: 10.3390/life12111692
75. Choi, HS, Jeon, HJ, Lee, OH, and Lee, BY. Dieckol, a major phlorotannin in Ecklonia cava, suppresses lipid accumulation in the adipocytes of high-fat diet-fed zebrafish and mice: Inhibition of early adipogenesis via cell-cycle arrest and AMPKα activation. Mol Nutr Food Res. (2015) 59:1458–71. doi: 10.1002/mnfr.201500021,
76. Moon, HE, Islam, N, Ahn, BR, Chowdhury, SS, Sohn, HS, Jung, HA, et al. Protein tyrosine phosphatase 1B and α-glucosidase inhibitory Phlorotannins from edible brown algae, Ecklonia stolonifera and Eisenia bicyclis. Biosci Biotechnol Biochem. (2011) 75:1472–80. doi: 10.1271/bbb.110137
77. Karthikeyan, A, Javaid, A, Tabassum, N, Kim, TH, Kim, YM, Jung, WK, et al. Marine-derived phlorotannins: sustainable inhibitors of multiple virulence factors in Pseudomonas aeruginosa. AMB Express. (2025) 15:162. doi: 10.1186/s13568-025-01963-w
78. Gabbia, D, and De Martin, S. Brown Seaweeds for the Management of Metabolic Syndrome and Associated Diseases. Molecules. (2020) 25:4182. doi: 10.3390/molecules25184182
79. Bae, JY, Seo, YH, and Oh, SW. Antibacterial activities of polyphenols against foodborne pathogens and their application as antibacterial agents. Food Sci Biotechnol. (2022) 31:985–97. doi: 10.1007/s10068-022-01058-3,
80. Mann, ER, Lam, YK, and Uhlig, HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. (2024) 24:577–95. doi: 10.1038/s41577-024-01014-8,
81. Wang, S, Kong, F, Zhang, X, Dai, D, Li, C, Cao, Z, et al. Disruption of hindgut microbiome homeostasis promotes postpartum energy metabolism disorders in dairy ruminants by inhibiting acetate-mediated hepatic AMPK-PPARA axis. Microbiome. (2025) 13:167. doi: 10.1186/s40168-025-02150-6
82. Nash, V, Ranadheera, CS, Georgousopoulou, EN, Mellor, DD, Panagiotakos, DB, McKune, AJ, et al. The effects of grape and red wine polyphenols on gut microbiota - A systematic review. Food Res Int Ott Ont. (2018) 113:277–87. doi: 10.1016/j.foodres.2018.07.019
83. Zhang, J, Zhang, W, Yang, L, Zhao, W, Liu, Z, Wang, E, et al. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function. Phytomedicine. (2023) 109:154589. doi: 10.1016/j.phymed.2022.154589,
84. Wu, Z, Wu, W, Yang, S, Cheng, F, Lv, J, Shao, Y, et al. Safety evaluation and effects of dietary phlorotannins on the growth, health, and intestinal microbiota of Litopenaeus vannamei. Fish Shellfish Immunol. (2024) 150:109569. doi: 10.1016/j.fsi.2024.109569
85. Catarino, MD, Marçal, C, Bonifácio-Lopes, T, Campos, D, Mateus, N, Silva, AMS, et al. Impact of phlorotannin extracts from Fucus vesiculosus on human gut microbiota. Mar Drugs. (2021) 19:375. doi: 10.3390/md19070375
86. Limijadi, EKS, Tjandra, KC, Permatasari, HK, Augusta, PS, Surya, R, Harbuwono, DS, et al. Marine-algal-derived postbiotics modulating the gut microbiota–adipose tissue axis in obesity: a new frontier. Nutrients. (2025) 17:3774. doi: 10.3390/nu17233774
87. Oh, S, Son, M, Byun, KA, Jang, JT, Choi, CH, Son, KH, et al. Attenuating effects of dieckol on high-fat diet-induced nonalcoholic fatty liver disease by decreasing the NLRP3 inflammasome and pyroptosis. Mar Drugs. (2021) 19:318. doi: 10.3390/md19060318
88. Gundala, NKV, Naidu, VGM, and Das, UN. Arachidonic acid and lipoxin A4 attenuate alloxan-induced cytotoxicity to RIN5F cells in vitro and type 1 diabetes mellitus in vivo. Biofactors. (2017) 43:251–71. doi: 10.1002/biof.1336,
89. Peng, C y. Extraction, phytochemicals characterization, in vivo and in vitro anti-diabetic ability of non-extractable polyphenols from Undaria pinnatifida. Food Res Int. (2024) 196:115021. doi: 10.1016/j.foodres.2024.115021
90. Attjioui, M, Ryan, S, Ristic, AK, Higgins, T, Goñi, O, Gibney, ER, et al. Comparison of edible brown algae extracts for the inhibition of intestinal carbohydrate digestive enzymes involved in glucose release from the diet. J Nutr Sci. (2021) 10:e5. doi: 10.1017/jns.2020.56,
91. Lordan, S, Smyth, TJ, Soler-Vila, A, Stanton, C, and Ross, RP. The α-amylase and α-glucosidase inhibitory effects of Irish seaweed extracts. Food Chem. (2013) 141:2170–6. doi: 10.1016/j.foodchem.2013.04.123,
92. Chen, J, Zhou, Z, Li, P, Ye, S, Li, W, Li, M, et al. Investigation of the potential phlorotannins and mechanism of six brown algae in treating type II diabetes mellitus based on biological activity, UPLC-QE-MS/MS, and network pharmacology. Foods. (2023) 12:3000. doi: 10.3390/foods12163000
93. Almutairi, MG, Aldubayan, K, and Molla, H. Effect of seaweed (Ecklonia cava extract) on blood glucose and insulin level on prediabetic patients: A double-blind randomized controlled trial. Food Sci Nutr. (2022) 11:983–90. doi: 10.1002/fsn3.3133,
94. Turck, D, Bresson, J, Burlingame, B, Dean, T, Fairweather-Tait, S, Heinonen, M, et al. Safety of Ecklonia cava phlorotannins as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. (2017) 15:e05003. doi: 10.2903/j.efsa.2017.5003
95. Shin, HC, Kim, SH, Park, Y, Lee, BH, and Hwang, HJ. Effects of 12-week oral supplementation of Ecklonia cava polyphenols on anthropometric and blood lipid parameters in overweight Korean individuals: a double-blind randomized clinical trial. Phytother Res PTR. (2012) 26:363–8. doi: 10.1002/ptr.3559,
96. Choi, EK, Park, SH, Ha, KC, Noh, SO, Jung, SJ, Chae, HJ, et al. Clinical trial of the hypolipidemic effects of a brown alga Ecklonia cava extract in patients with hypercholesterolemia. Int J Pharmacol. 11:798–805. doi: 10.3923/ijp.2015.798.805
97. Kim, YR, Park, MJ, Park, SY, and Kim, JY. Brown seaweed consumption as a promising strategy for blood glucose management: a comprehensive meta-analysis. Nutrients. (2023) 15:4987. doi: 10.3390/nu15234987
98. Rivera-Tovar, PR, Contreras-Contreras, G, Rivas-Reyes, PI, Pérez-Jiménez, J, Martínez-Cifuentes, M, Pérez-Correa, JR, et al. Sustainable recovery of phlorotannins from Durvillaea incurvata: integrated extraction and purification with advanced characterization. Antioxidants. (2025) 14:250. doi: 10.3390/antiox14030250
99. Paradis, ME, Couture, P, and Lamarche, B. A randomised crossover placebo-controlled trial investigating the effect of brown seaweed (Ascophyllum nodosum and Fucus vesiculosus) on postchallenge plasma glucose and insulin levels in men and women. Appl Physiol Nutr Metab. (2011) 36:913–9. doi: 10.1139/h11-115
100. Harasym, J, Słota, P, and Pejcz, E. Phlorotannins from Phaeophyceae: structural diversity, multi-target bioactivity, pharmacokinetic barriers, and nanodelivery system innovation. Mol Basel Switz. (2025) 30:4733. doi: 10.3390/molecules30244733
101. Lopes, G, Sousa, C, Silva, LR, Pinto, E, Andrade, PB, Bernardo, J, et al. Can phlorotannins purified extracts constitute a novel pharmacological alternative for microbial infections with associated inflammatory conditions? PLoS One. (2012) 7:e31145. doi: 10.1371/journal.pone.0031145,
102. Duan, R, Guan, X, Huang, K, Zhang, Y, Li, S, Xia, J, et al. Flavonoids from Whole-Grain Oat Alleviated High-Fat Diet-Induced Hyperlipidemia via Regulating Bile Acid Metabolism and Gut Microbiota in Mice. J Agric Food Chem. (2021) 69:7629–40. doi: 10.1021/acs.jafc.1c01813,
103. Xie, XM, Zhang, BY, Feng, S, Fan, ZJ, and Wang, GY. Activation of gut FXR improves the metabolism of bile acids, intestinal barrier, and microbiota under cholestatic condition caused by GCDCA in mice. Microbiol Spectr. (2025) 13:e0315024. doi: 10.1128/spectrum.03150-24,
104. Luo, J, Hou, Y, Xie, M, Ma, W, Shi, D, and Jiang, B. CYC31, A Natural Bromophenol PTP1B Inhibitor, Activates Insulin Signaling and Improves Long Chain-Fatty Acid Oxidation in C2C12 Myotubes. Mar Drugs. (2020) 18:267. doi: 10.3390/md18050267
105. Baraskar, K, Thakur, P, Shrivastava, R, and Shrivastava, VK. Ameliorative effects of gallic acid on GLUT-4 expression and insulin resistance in high fat diet-induced obesity animal model mice, Mus musculus. J Diabetes Metab Disord. (2023) 22:721–33. doi: 10.1007/s40200-023-01194-5
106. Duttaroy, AK. Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review. Nutrients. (2021) 13:144. doi: 10.3390/nu13010144,
107. Duncan, SH, Conti, E, Ricci, L, and Walker, AW. Links between diet, intestinal anaerobes, microbial metabolites and health. Biomedicine. (2023) 11:1338. doi: 10.3390/biomedicines11051338
108. Kimura, I, Ozawa, K, Inoue, D, Imamura, T, Kimura, K, Maeda, T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. (2013) 4:1829. doi: 10.1038/ncomms2852
109. Kim, M, Qie, Y, Park, J, and Kim, CH. Gut Microbial Metabolites Fuel Host Antibody Responses. Cell Host Microbe. (2016) 20:202–14. doi: 10.1016/j.chom.2016.07.001,
110. Li, H, Gao, J, Peng, W, Sun, X, Qi, W, and Wang, Y. Dietary Polyphenols-Gut Microbiota Interactions: Intervention Strategies and Metabolic Regulation for Intestinal Diseases. Biology. (2025) 14:1705. doi: 10.3390/biology14121705
Keywords: gut microbiota, metabolism, phloroglucinol, phlorotannins, polyphenols
Citation: Wu S, Sui Z, Pan J, Men X, Li X, Xue D, Meng Q, Han X and Shen Y (2026) Phlorotannins and glycolipid metabolism: comprehensive regulatory roles mediated by the gut microbiota. Front. Nutr. 13:1750434. doi: 10.3389/fnut.2026.1750434
Edited by:
Jasmina D. Debeljak Martacic, University of Belgrade, SerbiaCopyright © 2026 Wu, Sui, Pan, Men, Li, Xue, Meng, Han and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xionggao Han, eGlvbmdnYW80MTRAaG90bWFpbC5jb20=; Yimin Shen, c2hlbjA2QHpqdS5lZHUuY24=
†These authors have contributed equally to this work